



**Kunwar Shailubhai, Ph.D. & MBA**

**Email:** Shailubhai@gmail.com

**Mobile:** 1+ (347) 748 3717

<https://www.linkedin.com/in/kunwar-shailubhai-7413154/>

## FUNCTIONAL PROFILE

- An experienced executive (Co-founder, CEO & CSO) with 30+ years of R&D experience with demonstrated history of '**Bench to Market**' in start-up Biotech and Big pharma.
- Research experience in Inflammation, oncology, neurodegenerative and lung diseases
- Successfully advanced two start up biotech companies to NASDAQ listing. These endeavors required establishing R&D pipeline, in-licensing assets, educating investment community, developing relationships with investment firms, research analysts & KOL and then successfully completing financings.
- Co-founded Synergy Pharmaceuticals (NASDAQ: SGYP) to further develop my pioneering scientific discovery for treatment of gastrointestinal diseases. Led teams from preclinical discovery, non-clinical & clinical development, intellectual property management and NDA submission for FDA approval of my first drug TRULANCE®. Also invented Dolcanatide, a GCRA drug candidate, which has successfully completed phase 2 clinical trial.
- Invented '**Revolutionary Technologies**' for monoclonal antibody therapeutics (oral, nasal and inhalation immunotherapies) for Crohn's Disease, neurodegenerative and autoimmune diseases. These inventions built the current R&D pipeline of Tiziana Life Sciences (NASDAQ: TLSA)
- Invented, developed, and patented innovative technology to enhance the success of CAR-T/CAR-NK for cancer treatment. Successfully licensed the technology and negotiated a long-term multi-million commercial agreement with Precision Biosciences (NASDAQ: DTIL)
- Executive director of Board and CEO, Rasna therapeutics. A publicly listed biotechnology company focusing on development of drug candidates for AML. The inventor of a nanoparticle-based formulation of a compound for AML/MDS treatment.
- As an executive director of Board, started Okyo Pharma (NASDAQ: OKYO), build pipeline and invented an agonist of G-protein coupled receptor (GPCR) for treatment of eye diseases.
- Attended national and international conferences (JP Morgan, BIO, Jeffreys, Cowan's, LT Micro and BIO Europe) with one-on-one meetings with investors/investment firms. Travel extensively in the EU, Asia and US for financing related activities and to develop relationships with investment firms.
- 40+ issued patents, 20+ patent applications (pending) and 50+ research articles.

## Member, Board of directors and scientific advisory council

1. Executive director of Director of Board, Okyo Pharmaceuticals, a biotechnology company focusing on development of non-opioid analgesic and a drug for treatment of dry eye disease. An inventor of a drug candidate for dry eye treatment
2. Non-executive director of board, Accustem Sciences, a biotechnology company developing kit for cancer diagnosis.
3. Non-executive director of board, GenSignia BioSciences. A biotechnology company focusing on the development of diagnostic kits for human cancers.
4. Member of Scientific Advisory council of Baruch S. Blumberg Institute, Doylestown, PA

## PROFESSIONAL EXPERIENCE

**Senior Advisor and Professor (August 1, 2022, to Current)**

Baruch S. Blumberg institute and PA Biotechnology center, Doylestown, PA 18902, USA

- Advising management of the institute in Scientific portfolio
- Developed a 12-weeks course in Pharma R&D programs. The purpose of this course is to train students and early-stage researchers for careers in pharma and biotechnology companies.

**CEO & CSO** (May 25, 2017, to August 2022)

Tiziana Life Sciences (LON: TILS and NASDAQ: TLSA), Philadelphia & New York city, USA and London, UK

### **Key Achievements**

- Built strong pipeline by in-licensing technologies and by further developing proprietary technologies to build strong intellectual property.
- Successfully led the company for IPO and NASDAQ listing and financing (\$ 87.5 M).
- Invented and developed an innovative technology to enhance the success of CAR-T for cancer treatment. Successfully licensed the technology to Precision Biosciences (NASDAQ: DTIL) and negotiated a multi-million commercial agreement with the company, a lucrative revenue source for Tiziana.
- Negotiated a research agreement with Bristol Myers Squibb to save Tiziana multi-million dollars in licensing fees.
- Successfully completed five clinical trials with positive results in different disease indications
- Implemented open, transparent, and accountable practices to facilitate strong team culture.
- Managed relationships with investment firms, KOLs, investors, IP, and legal counsels. Ensured company was meeting all legal requirements and regulatory affairs

**Co-founder, EVP and CSO** (May 2000 to May 2017)

Synergy Pharmaceuticals (NASDAQ: SYGP), Philadelphia and New York, USA

### **Key Achievements**

- Co-founded the company on my pioneering discovery related to therapeutic applications of guanylate cyclase-C agonists (GCRA), developed strong IP estate, hired, trained, and directed scientific staff to complete preclinical to clinical development leading to FDA approval of Trulance®.
- Invented Dolcanatide and successfully completed pre-clinical, IND-enabling studies, Phase 1 and Phase 2 clinical studies.
- Worked with CEO and business development team for several rounds of financings from domestic and global investors (US, EU, China and Japan). Successfully led the team for IPO on NASDAQ listing in 2012.
- In 2017, inducted in 'Wall of Fame' at the Baruch S. Blumberg Institute, PA, USA. An honor granted to scientist of excellence and discoverers of new drugs.
- Recognized by Pennsylvania government for stimulating economic activities in Doylestown, PA
- Directed team to build strong intellectual property estate to secure proprietary technologies for the company. Chief architect of IP estate with 30+ issued patents and 30+ patent applications.

**Group Leader:** Cancer Group, March 1993 to October 1999

Monsanto Company (G. D. Searle & Co), St. Louis, USA

### **Key Achievements**

- Led scientific team for a variety of projects in inflammation and oncology research.
- First to explore therapeutic applications of Celebrex® for cancers (colon, prostate and breast). The drug was eventually approved for familial adenomatous polyposis (FAP; colon cancer)
- Pioneered therapeutic applications of Uroguanylin, an agonist of Guanylate Cyclase-C (GCRA)

- Led a team of 22 members to develop Uroguanylin for treatment of chronic constipation and irritable bowel syndrome-constipation.

### Other positions

**Sr. Staff Fellow, 1991-1993:** National Institute of Health (NIH), Bethesda, Maryland, USA

**Assistant Research Scientist (Asst Prof. of Research) 1988-1990:** University of Maryland, College Park, USA.

**Post-doctoral Fellow, 1985-1988:** University of Maryland, College Park, USA.

**Sr. Scientist (1984-85),** Hindustan Lever (Unilever), Mumbai (Bombay), India

### Joint Appointments

1. **Professor (2004-current),** Baruch S. Blumberg Institute, Doylestown, PA., USA

2. **Adjunct Professor (2004-current),** Drexel School of Medicine, Philadelphia, PA., USA

### EDUCATION

#### Master of Business Administration (While working at Monsanto)

University of Missouri at St. Louis (UMSL) and Fox School of Business, Temple University at Philadelphia, USA.

**Completion:** 2002

#### Doctor of Philosophy (Ph.D. in Microbiology)

M. S. University of Baroda, Vadodara, India.

**Completion:** 1984

#### Master of Science (M.Sc. in Microbiology)

M. S. University of Baroda, Vadodara, India.

**Completion:** 1978

#### Bachelor of Science (B. Sc. in Biology)

University of Udaipur, Udaipur, India.

**Completion:** 1976

### Honors

1. **Inducted to 'Wall of Fame' at the PA Biotech Center, Doylestown, PA 18902.** This honorable recognition is given to scientists who have immensely contributed to science.
2. **Recognition by Pennsylvania state:** This recognition was given for stimulating biotechnology and economic activities in Doylestown, PA.
3. **Keynote lecture at the TIDES 2015**
4. **Plenary lectures:** More than 30 plenary invited presentations at national and international scientific conferences.
5. **Invited lectures:** Several (100+) invited lectures at academic and biotechnology companies in USA, UK, Israel, and India.

### NIH Study Sections:

**Member,** Special emphasis study section for biodefense research ZAI1-GSM-M (M1)

**Member,** Special emphasis study section for Digestive Diseases Research ZRG1 DIG-A 10B

**Chairperson,** Special emphasis study section for biodefense research ZAI1-LW-M-M1

**Member**, Special emphasis study section for biodefense research, 2007

**Member**, Study section for DMID-NIAID-NIH-AI20080022-BARDA

**Member**, Special emphasis study section for biodefense research ZAI1 LR M M1 1, Jan 26, 2010

**Member**, Study section RFP NIAID-DMID-NIHAI2009066 "In vitro Assessments for Antimicrobial Activity.

**Member**, Study section BAA-NIAID-DMID-NIHAI2010097 "Development of Therapeutics for Biodefense" January 2011

**Member**, Study section on "Provocative questions for cancer biology, NCI. 2011.

**Member**, NIAID Special emphasis panel "Development of Therapeutic Candidates for Biodefense, AMR Infections, and Emerging Infectious Diseases" September 7-11, 2022

**Patents and patent applications:**

**50+** world-wide issued patents and **25+** patent applications. Available for review at:

[http://www.freepatentsonline.com/result.html?p=1&sort=relevance&srch=top&query\\_txt=Shailubhai&patents\\_us=on](http://www.freepatentsonline.com/result.html?p=1&sort=relevance&srch=top&query_txt=Shailubhai&patents_us=on)

**Publications:**

**50+** publications. Available for review at my NIH bibliography

<https://www.ncbi.nlm.nih.gov/myncbi/1h7AcTTXk9m5Kt/bibliography/public/>

**VIDEO PRESENTATIONS AND INTERVIEWS: These may be viewed at:**

[https://www.youtube.com/results?search\\_query=Kunwar+Shailubhai](https://www.youtube.com/results?search_query=Kunwar+Shailubhai)

**Ad Hoc journal reviewer:** Nature Biotechnology, J. Biological Chemistry, Glycobiology, Trends In Biotechnology, Scan. J. Gastroenterol., Leukemia Research, Pancreas, Oncology, Eur J Pharmacology and World J. Gastroenterol.